Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Literature
1.
Rasul S, Korn S. Imaging and therapy targeting PSMA receptors: See better and treat more precisely. memo. 2023;16(4). DOI.
2.
Hübner N, Korn S, Rajwa P, Shariat SFD. Focal Therapy in intermediate- and high-risk Prostate cancer. memo. 2023;16(3). DOI.
3.
Metadata
Title
Prostate cancer special—part 1
Author
Prof. Dr. Shahrokh F. Shariat
Publication date
01-12-2023
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 4/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00923-z

Other articles of this Issue 4/2023

memo - Magazine of European Medical Oncology 4/2023 Go to the issue

short review

Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment

editorial

ASCO 2023—partnering with patients: the cornerstone of cancer care and research

short review

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

short review

Renal cell carcinoma

short review

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

short review

Management of malignant hypercalcemia in cancer patients—a short review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits